Intellectual Property Industries

Bar Admissions

  • New York
  • District of Columbia

Court Admissions

  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Southern District of New York
  • U.S. Court of Federal Claims

Education

  • J.D., cum laude, University of Notre Dame Law School, 1999
  • B.S., Chemistry, High Distinction, University of Illinois Urbana-Champaign, 1996
  • B.S., Biochemistry, University of Illinois Urbana-Champaign, 1996
T +1 212.218.2571
F +1 212.218.2200
 

Ha Kung Wong

Partner

Ha Kung Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation in pharmaceuticals, biologics and chemistry. Cases Ha Kung has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives and other pharmaceuticals. Ha Kung also has extensive experience with inter partes review (IPR), intellectual property counseling, pre-suit investigations, licensing and due diligence.

Ha Kung is the recipient of the 2017 ILO Client Choice Individual Award for Intellectual Property in New York. He currently serves as faculty for NITA (the National Institute of Trial Advocacy) and Lawline, and has been named a "Furthered 40" by Lawline for his contributions. He is also an Advisory Board Member for The Center for Biosimilars. Additionally, Ha Kung is a member of the Venable Board.

Ha Kung was named to The National Law Journal's 2017 inaugural list of Elite Boutique Trailblazers.

Representative Clients

  • Alkermes
  • Allergan
  • Alnylam
  • Materia
  • UCB

Significant Matters

  • Allergan against Wilshire, Somerset and Aurobindo on patents relating to ophthalmic formulations of alcaftadine for once daily treatment of allergic conjunctivitis.
  • Alnylam against Silence Therapeutics on patents relating to RNAi technology.
  • AstraZeneca against Andrx, Genpharm, Dr. Reddy and Schwartz Pharma on patents relating to omeprazole and its formulations.
  • Bristol-Myers Squibb against The Regents of the University of Michigan and Repligen Corp. and ZymoGenetics on patents relating to synthetic fusion proteins for regulating the immune system.
  • UCB against Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to levetiracetam, a leading epilepsy medicine.
  • GlaxoSmithKline against Barr Pharmaceuticals on patents relating to dutasteride, a leading BPH drug.
  • UCB and Celltech against KV Pharmaceutical on patents relating to methylphenidate hydrochloride, an ADHD medicine.